业务转型咨询
in HealthTech & Digital Health

简短回答

数字健康领域多数旨在保护风险收入份额或控制客户流失的项目，在诊断阶段就已失败，因为诊断往往由后续负责补救定价的同一家公司承接。 数字健康公司面临的结构性难题在于：结果风险承诺的签署速度，超过了公司验证自身能否承担这些风险的学习速度——12个月的测量窗口对上11个月的销售周期。因此任何可信方案都必须同时把握风险收入份额与参与率，而这正是多数内部分析停滞之处，因为两者分属不同系统。

转型项目包含三项独立工作：找出已签署风险合同下参与率和毛利率下滑的原因，决定首先调整哪些环节，以及提供执行所需的能力。供应商将三者打包，是因为审查阶段的定价本就为了赢得后续交付合同，这种结构奖励扩大付费工作范围的诊断，而非缩小范围。

这一模式反复出现的原因在于，公司以11个月销售周期签署结果承诺，而检验承诺能否兑现所需的数据却在12个月测量周期后才到。结果是，关于哪些参保成员真正带来正向结果、哪些合同条款侵蚀利润的问题，尚未得到答案就已转为交付计划。

检验标准是CEO或CFO能否已列出推动风险份额和客户流失向坏方向变化的两三个因素，并附上对利润的影响。当这份清单存在时，额外交付能力就是 straightforward 的采购；当清单不存在时，先行投入实施只会以更大规模锁定现有合同条款。

企业战略与转型提供缺失的分配视图：340,000名参保成员的收入与成本如何分布，哪些细分群体支撑当前风险义务，以及会改变这些数字的调整顺序。它止步于建议，并在需要40人九个月时明确说明，避免第一张发票先确认更大范围。

如何判断这确实是你的问题

这三者同时出现才是标志。单独一个通常指向其他问题。

✓ 预测中风险收入份额承诺持续上升，而按队列划分的参与率数据仍不完整或未与这些承诺关联。
✓ 范围界定文件已按部门或供应商列出工作流，而非按PMPM利润率或客户流失的具体驱动因素。
✓ 下一次续约或新合同定价时，当前队列的归因结果尚未完成测量窗口。

通常会让情况更糟的做法。 诊断工作委托给后续竞标交付的同一家公司，导致推荐范围按供应商交付能力而非参与率或利润缺口来确定。

Who this is for — and who it is not

It is for you if you run or finance a digital health company and the word "transformation" is being used before anyone has agreed what is broken. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.

It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.

实际运行分析时的样子

Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.

The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.

This is one move out of a full analysis. Read a complete report — every page, no email required.

引擎如何处理这个问题

This question routes to 企业战略与转型, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.

You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.

人们关于此问题的常见提问

业务转型咨询实际花费多少？

对中型市场公司而言，仅诊断阶段通常在六至十周内花费£75k–£250k，后续交付阶段通常是其数倍。大公司日费率大致为顾问£1,500–£3,500、合伙人£4,000–£8,000，典型团队混合两者，有效费率居中。但关键数字不是日费率，而是诊断与交付的比例，因为范围正是在此处被设定。

软件能否取代转型咨询？

不能，任何声称能取代的工具都在推销。软件无法运行项目办公室、与事业部总经理进行艰难对话，或提供40人九个月的能力。它能做的是生成决定是否需要这些资源以及指向何处的分析——而这部分最常被仓促处理，也最容易因错误而付出高昂代价。

如何控制范围？

诊断与交付分开采购，并在接受交付报价前书面记录决策。一旦两三个调整被明确且算术写在纸上，交付招标就是有固定简报的采购流程。一旦未明确，招标会自行设定简报，且总是更大的范围。

Is this different in healthtech & digital health than in other industries?

Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.

What data do I need before this analysis is worth running for a digital health company?

Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.

When is Percision the wrong tool?

Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.

Does Percision replace a lawyer, tax advisor, auditor, or AI implementation team?

Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.